Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children

Detalhes bibliográficos
Autor(a) principal: Justino, Maria Cleonice Aguiar
Data de Publicação: 2012
Outros Autores: Araújo, Eliete da Cunha, Doorn, Leen-Jan Van, Oliveira, Consuelo Silva de, Gabbay, Yvone Benchimol, Mascarenhas, Joana D'Arc Pereira, Miranda, Yllen S, Guerra, Sylvia de Fátima dos Santos, Silva, Veronilce B da, Linhares, Alexandre da Costa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Digital do Instituto Evandro Chagas (Patuá)
Texto Completo: https://patua.iec.gov.br/handle/iec/3271
Resumo: In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328) or two doses of placebo (n = 325) at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3 per cent [95 per cent confidence interval (CI) 37.5-89.1per cent] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8 per cent (95 per cent CI 36.4-96.6 per cent) against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Belém during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains.
id IEC-2_f03ab979d949b93dc9065c9326b8d8d5
oai_identifier_str oai:patua.iec.gov.br:iec/3271
network_acronym_str IEC-2
network_name_str Repositório Digital do Instituto Evandro Chagas (Patuá)
repository_id_str
spelling Justino, Maria Cleonice AguiarAraújo, Eliete da CunhaDoorn, Leen-Jan VanOliveira, Consuelo Silva deGabbay, Yvone BenchimolMascarenhas, Joana D'Arc PereiraMiranda, Yllen SGuerra, Sylvia de Fátima dos SantosSilva, Veronilce B daLinhares, Alexandre da Costa2018-07-19T17:03:15Z2018-07-19T17:03:15Z2012JUSTINO, Maria Cleonice Aguiar et al. Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memórias do Instituto Oswaldo Cruz, v. 107, n. 7, p. 846-853, Nov. 2012.0074-0276https://patua.iec.gov.br/handle/iec/327110.1590/S0074-02762012000700002In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328) or two doses of placebo (n = 325) at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3 per cent [95 per cent confidence interval (CI) 37.5-89.1per cent] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8 per cent (95 per cent CI 36.4-96.6 per cent) against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Belém during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains.IEC, SVS, GlaxoSmithKline BiologicalsMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Universidade Federal do Pará. Belém, PA, Brasil.DDL Diagnostic Laboratory. Voorburg, The Netherlands.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.engInstituto Oswaldo CruzOral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian childreninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleRotavirusVacinas contra Rotavirus / isolamento & purificaçãoGastroenteriteinfo:eu-repo/semantics/openAccessreponame:Repositório Digital do Instituto Evandro Chagas (Patuá)instname:Instituto Evandro Chagas (IEC)instacron:IECORIGINALOral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children.pdfOral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children.pdfapplication/pdf445376https://patua.iec.gov.br/bitstreams/163f40ce-b5fe-4988-a97f-d5ba2970d84e/downloadc22b606cdd0f069b4de33031b42c3d04MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-871https://patua.iec.gov.br/bitstreams/21a1bd4e-7090-4acc-b69f-6c1c8ece87ae/download52f1732ea66fbd1123abe39f5373b797MD52TEXTOral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children.pdf.txtOral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children.pdf.txtExtracted texttext/plain42691https://patua.iec.gov.br/bitstreams/dabc0787-cc75-416c-99ce-853502199bd3/download7564c48da07047b57cf15b8de6b69e7dMD55THUMBNAILOral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children.pdf.jpgOral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children.pdf.jpgGenerated Thumbnailimage/jpeg5983https://patua.iec.gov.br/bitstreams/fae9f68b-f900-45aa-a0de-435649efc39d/download8a7c1c166d6db57638ab16ffc0246520MD56iec/32712023-06-07 14:10:15.507oai:patua.iec.gov.br:iec/3271https://patua.iec.gov.brRepositório InstitucionalPUBhttps://patua.iec.gov.br/oai/requestclariceneta@iec.gov.br || Biblioteca@iec.gov.bropendoar:2023-06-07T14:10:15Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC)falseVG9kb3Mgb3MgZG9jdW1lbnRvcyBkZXNzYSBjb2xlw6fDo28gc2VndWVtIGEgTGljZW7Dp2EgQ3JlYXRpdmUgY29tbW9ucy4=
dc.title.pt_BR.fl_str_mv Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children
title Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children
spellingShingle Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children
Justino, Maria Cleonice Aguiar
Rotavirus
Vacinas contra Rotavirus / isolamento & purificação
Gastroenterite
title_short Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children
title_full Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children
title_fullStr Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children
title_full_unstemmed Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children
title_sort Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children
author Justino, Maria Cleonice Aguiar
author_facet Justino, Maria Cleonice Aguiar
Araújo, Eliete da Cunha
Doorn, Leen-Jan Van
Oliveira, Consuelo Silva de
Gabbay, Yvone Benchimol
Mascarenhas, Joana D'Arc Pereira
Miranda, Yllen S
Guerra, Sylvia de Fátima dos Santos
Silva, Veronilce B da
Linhares, Alexandre da Costa
author_role author
author2 Araújo, Eliete da Cunha
Doorn, Leen-Jan Van
Oliveira, Consuelo Silva de
Gabbay, Yvone Benchimol
Mascarenhas, Joana D'Arc Pereira
Miranda, Yllen S
Guerra, Sylvia de Fátima dos Santos
Silva, Veronilce B da
Linhares, Alexandre da Costa
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Justino, Maria Cleonice Aguiar
Araújo, Eliete da Cunha
Doorn, Leen-Jan Van
Oliveira, Consuelo Silva de
Gabbay, Yvone Benchimol
Mascarenhas, Joana D'Arc Pereira
Miranda, Yllen S
Guerra, Sylvia de Fátima dos Santos
Silva, Veronilce B da
Linhares, Alexandre da Costa
dc.subject.decsPrimary.pt_BR.fl_str_mv Rotavirus
Vacinas contra Rotavirus / isolamento & purificação
Gastroenterite
topic Rotavirus
Vacinas contra Rotavirus / isolamento & purificação
Gastroenterite
description In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328) or two doses of placebo (n = 325) at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3 per cent [95 per cent confidence interval (CI) 37.5-89.1per cent] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8 per cent (95 per cent CI 36.4-96.6 per cent) against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Belém during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains.
publishDate 2012
dc.date.issued.fl_str_mv 2012
dc.date.accessioned.fl_str_mv 2018-07-19T17:03:15Z
dc.date.available.fl_str_mv 2018-07-19T17:03:15Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv JUSTINO, Maria Cleonice Aguiar et al. Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memórias do Instituto Oswaldo Cruz, v. 107, n. 7, p. 846-853, Nov. 2012.
dc.identifier.uri.fl_str_mv https://patua.iec.gov.br/handle/iec/3271
dc.identifier.issn.-.fl_str_mv 0074-0276
dc.identifier.doi.-.fl_str_mv 10.1590/S0074-02762012000700002
identifier_str_mv JUSTINO, Maria Cleonice Aguiar et al. Oral live attenuated rotavirus vaccine (RotarixTM) offers a sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memórias do Instituto Oswaldo Cruz, v. 107, n. 7, p. 846-853, Nov. 2012.
0074-0276
10.1590/S0074-02762012000700002
url https://patua.iec.gov.br/handle/iec/3271
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Instituto Oswaldo Cruz
publisher.none.fl_str_mv Instituto Oswaldo Cruz
dc.source.none.fl_str_mv reponame:Repositório Digital do Instituto Evandro Chagas (Patuá)
instname:Instituto Evandro Chagas (IEC)
instacron:IEC
instname_str Instituto Evandro Chagas (IEC)
instacron_str IEC
institution IEC
reponame_str Repositório Digital do Instituto Evandro Chagas (Patuá)
collection Repositório Digital do Instituto Evandro Chagas (Patuá)
bitstream.url.fl_str_mv https://patua.iec.gov.br/bitstreams/163f40ce-b5fe-4988-a97f-d5ba2970d84e/download
https://patua.iec.gov.br/bitstreams/21a1bd4e-7090-4acc-b69f-6c1c8ece87ae/download
https://patua.iec.gov.br/bitstreams/dabc0787-cc75-416c-99ce-853502199bd3/download
https://patua.iec.gov.br/bitstreams/fae9f68b-f900-45aa-a0de-435649efc39d/download
bitstream.checksum.fl_str_mv c22b606cdd0f069b4de33031b42c3d04
52f1732ea66fbd1123abe39f5373b797
7564c48da07047b57cf15b8de6b69e7d
8a7c1c166d6db57638ab16ffc0246520
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC)
repository.mail.fl_str_mv clariceneta@iec.gov.br || Biblioteca@iec.gov.br
_version_ 1787533057742340096